Regeneus announces United States Patent Office decision to allow patent for Progenza

Tuesday, 10 July 2018

Issuance of the patent for United States Patent Application No. 14/342479 entitled ‘Therapeutics using adipose cells and cell secretions’ will provide commercial rights in the United States through to 2032.
Corresponding patents have been granted in Australia and Japan and are being pursued for grant in other key territories including Europe.

Progenza is the company’s lead cell therapy technology platform being developed for the treatment of osteoarthritis and other musculoskeletal diseases. It has the potential to be used for other inflammatory diseases that have limited treatment options.

Progenza is made from expanded allogeneic mesenchymal stem cells (MSCs) from human adipose tissue and contains the bioactive secretions of the cells. Progenza cells work by secreting cytokines, growth factors and exosomes to reduce inflammation and pain and promote healing and repair in the damaged
or diseased tissue. It is a scalable technology that has the demonstrated capability to produce millions of doses of cells from a single donor.

In December 2016, Regeneus announced a strategic collaboration and licensing agreement with AGC of Japan, a leading global biopharmaceutical manufacturer, for the exclusive rights to manufacture Progenza for all clinical applications in Japan. Regeneus is in advanced negotiations with potential
clinical licensees of Progenza for Japan.

Regeneus has in excess of 70 patents or patent applications across multiple patent families which provides a substantial competitive advantage for the company’s product pipeline.